Navigation Links
Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial
Date:5/12/2008

Hamilton, ON (May 12, 2008) - Beta-blocker drugs may help prevent heart attacks during surgery, but they may increase the risk of death and major stroke, says a major study to be published online today by the prestigious medical journal, The Lancet.

POISE is the worlds largest randomized trial addressing perioperative cardiac complications. POISE evaluated the effects of a beta-blocker versus placebo given to patients around the time of surgery.

POISE demonstrates that a beta-blocker given around the time of surgery decreases a patients risk of a heart attack but increases their risk of a major stroke and death, said Dr. P.J. Devereaux, POISE co-principle investigator, McMaster University, Hamilton, Canada.

Worldwide approximately 100 million adults have major non-cardiac surgery (i.e., all surgeries excluding heart surgeries) each year. Among them, more than one million will suffer a major heart complication such as a heart attack or death.

Surgery increases patients catecholamines, or stress hormones, which increase the hearts requirement for oxygen. The stress on the heart can lead to serious events like a heart attack. Because beta-blockers reduce the effects of increased catecholamines some physicians believed they may prevent serious heart complications around the time of surgery.

Initial small trials suggested beta-blockers were beneficial around the time of surgery but more recent moderate sized trials did not show any benefit, Dr. Homer Yang, POISE co-principal investigator, University of Ottawa, Ottawa, Canada. We undertook POISE to provide a clearer understanding of the effects of a beta-blocker around the time of surgery.

A major accomplishment of POISE was that anesthesiologists, cardiologists, internists, and surgeons at 190 centres in 23 countries came together and randomized 8,351 patients - more than 4 times as many patients than all the previous perioperative beta-blocker trials combined. Such efforts are rare, but essential in order to make progress in the management of these patients, said Dr. Salim Yusuf, POISE steering committee chair, McMaster University, Hamilton, Canada.

The POISE Trial randomized 4,174 patients to receive extended-release metoprolol succinate and 4,177 patients to receive placebo starting two to four hours before surgery and continuing for 30 days after surgery.

Fewer patients in the metoprolol group (176) than in the placebo group (239) suffered a heart attack, indicating that patients receiving metoprolol were 27 percent less likely to suffer a heart attack. However, 129 metoprolol patients compared to 97 placebo patients died, indicating that patients receiving metoprolol were 33 percent more likely to die. Further, 41 metoprolol patients versus 19 placebo patients suffered a stroke, indicating that patients receiving metoprolol had more than double the risk of a stroke.

Considering the heart attacks less than one-third of these patients also had a complication of their heart attack like heart failure. In contrast more than half of the patients who suffered a stroke were left incapacitated or needing help with everyday activities.

The POISE results suggest for every 1,000 patients with a similar risk profile who have noncardiac surgery, metoprolol will prevent 15 patients from having a heart attack, three from having angioplasty or coronary artery bypass surgery, and seven from developing new atrial fibrillation (a heart rhythm disorder).

The results also suggest that for every 1,000 patients, metoprolol would cause eight patients to die, five patients to have a stroke, 53 patients to experience a low blood pressure that would require treatment, and 42 patients to experience a low heart rate that would require treatment. Analysis of the POISE data suggests that metoprolol increased the risk of death and stroke by increasing the risk of the low blood pressures that required treatment.

Considering these results, patients are unlikely to accept the risks associated with perioperative metoprolol seen in POISE, said Dr. Gordon Guyatt, POISE outcome adjudication committee chair, McMaster University, Hamilton, Canada.

Considering the implications of the POISE results Dr. Devereaux stated, For more than a decade guidelines have recommended giving beta-blockers to patients having noncardiac surgery. Even if only 10% of physicians acted on the guideline recommendations throughout the last decade, 100 million patients would have received a beta-blocker around the time of surgery. If the results of POISE are widely applicable, throughout the last decade 800,000 patients would have died prematurely and 500,000 patients would have suffered a stroke because they were given a beta-blocker around the time of surgery.

This highlights the risk in assuming a perioperative beta-blocker regimen has benefit without substantial harm, and the importance and need for large randomized trials in the surgical setting.

The results are a real surprise, and will change how patients are cared for after their surgery, said Dr. Peter Liu, Scientific Director at the Canadian Institutes of Health Research. These results should make us question whether there are better alternatives for these patients. This is a good example of how a carefully conducted clinical study can entirely change how patients are cared for.


'/>"/>

Contact: Veronica McGuire
vmcguir@mcmaster.ca
90-552-591-402-2169
McMaster University
Source:Eurekalert

Related medicine news :

1. Bicyclist to Stop in DC during 9,000 Mile Lap Around the U.S.
2. Health Organizations Join Forces Around Quit-Smoking Help
3. Bicyclist Will Conclude 9,000 Mile Lap Around the U.S. on Sunday in New York City
4. Children Around the Globe Walk Toward a Lifetime of Healthy Habits
5. Negative Publicity Around PFFS Sales Practices Not Getting Through to Seniors
6. Galderma Associates Itself to Cartiers Womens Initiative Awards to Recognize Female Entrepreneurs From Around the Globe
7. Take a Culinary Trip Around the World for a Good Cause: March of Dimes
8. Safe Crossing Week 2007 Teaches Kids How to Behave Safely Around Trains
9. New Poll Shows Catholics Around the World Believe Good Catholics Can Use Condoms
10. Researchers From Around the World Gather to Discuss Triple Negative Breast Cancer
11. Area Around Breast Tumor May Predict Cancers Spread
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/25/2016)... ... June 25, 2016 , ... First Choice Emergency Room , the ... Ogunleye, as the Medical Director of its new Mesquite-Samuell Farm facility. , “We ... new Mesquite location,” said Dr. James M. Muzzarelli, Executive Medical Director of First Choice ...
(Date:6/25/2016)... ... , ... On Friday, June 10, Van Mitchell, Secretary of the Maryland Department ... in recognition of their exemplary accomplishments in worksite health promotion. , The Wellness at ... Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one of 42 ...
(Date:6/24/2016)... ... , ... Those who have experienced traumatic events may suffer from a complex ... as drug or alcohol abuse, as a coping mechanism. To avoid this pain and ... a traumatic event. , Trauma sufferers tend to feel a range of emotions, from ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Pulmonary Hypertension ... that it will receive two significant new grants to support its work to ... its 25th anniversary by recognizing patients, medical professionals and scientists for their work ...
(Date:6/24/2016)... ... June 24, 2016 , ... Comfort Keepers® of San Diego, CA is ... Road To Recovery® program to drive cancer patients to and from their cancer treatments. ... the highest quality of life and ongoing independence. Getting to and from medical ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... Mass. , June 24, 2016   Pulmatrix, ... pharmaceutical company developing innovative inhaled drugs, announced today that ... Russell Investments reconstituted its comprehensive set of ... "This is an important milestone for Pulmatrix," ... will increase shareholder awareness of our progress in developing ...
(Date:6/24/2016)... 24, 2016  Arkis BioSciences, a leading innovator ... more durable cerebrospinal fluid treatments, today announced it ... funding is led by Innova Memphis, followed by ... private investors.  Arkis, new financing will accelerate the ... market release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... June 23, 2016 Research and Markets ... Market - Forecast to 2022" report to their offering. ... method for the patients with kidney failure, it replaces the ... from the patient,s blood and thus the treatment helps to ... chloride in balance. Increasing number of ESRD ...
Breaking Medicine Technology: